Oxford Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Oxford Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$789K	Buy	+1,265	New	+$861K	0.39%	60
2025 Q2	–	Sell	-550	Closed	-$349K	–	728
2025 Q1	$349K	Buy	550 +207	+60%	+$142K	0.16%	217
2024 Q4	$244K	Buy	+343	New	+$288K	0.11%	309
2024 Q1	–	Sell	-704	Closed	-$618K	–	341
2023 Q4	$618K	Buy	+704	New	+$580K	0.93%	24
2020 Q1	–	Sell	-4,252	Closed	-$1.6M	–	1059
2019 Q4	$1.6M	Buy	+4,252	New	+$1.43M	0.04%	562
2019 Q3	–	Sell	-1,214	Closed	-$380K	–	1915
2019 Q2	$380K	Sell	1,214 -18,929	-94%	-$6.3M	0.01%	1377
2019 Q1	$8.27M	Buy	+20,143	New	+$8.29M	0.18%	127
2018 Q4	–	Sell	-769	Closed	-$312K	–	2042
2018 Q3	$312K	Sell	769 -364	-32%	-$139K	0.01%	1485
2018 Q2	$393K	Sell	1,133 -1,766	-61%	-$552K	0.01%	1425
2018 Q1	$998K	Buy	2,899 +143	+5%	+$49.7K	0.02%	942
2017 Q4	$1.05M	Buy	+2,756	New	+$1.12M	0.02%	904
2014 Q4	–	Sell	-5,733	Closed	-$2.06M	–	767
2014 Q3	$2.06M	Buy	+5,733	New	+$1.92M	0.05%	366

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Oxford Asset Management's REGN Position: Q2 2026 in Review

Oxford Asset Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 1,265 shares worth $789K. The stake represents 0.39% of the portfolio and ranks #60 among its holdings. This is a return to the name: Oxford Asset Management previously reported a position in REGN as recently as Q1 2025.

Oxford Asset Management first reported a position in REGN in Q3 2014 and has held it in 12 quarters since. The position peaked at $8.27M in Q1 2019. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Oxford Asset Management held 1,265 shares of Regeneron Pharmaceuticals worth $789K as of Q2 2026.
Regeneron Pharmaceuticals was a new Oxford Asset Management position in Q2 2026.
Regeneron Pharmaceuticals made up 0.39% of Oxford Asset Management's portfolio in Q2 2026, its #60 holding.
Oxford Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2014 and has held it in 12 quarters since.
Oxford Asset Management's Regeneron Pharmaceuticals position peaked at $8.27M in Q1 2019.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.